Open Access. Powered by Scholars. Published by Universities.®
- Institution
Articles 1 - 3 of 3
Full-Text Articles in Medicine and Health Sciences
Mutation And Variant Of Coronavirus Disease 2019 (Covid-19): Review Of Current Literatures, Adityo Susilo, Chyntia Olivia Maurine Jasirwan, Syahidatul Wafa, Suzy Maria, Wulyo Rajabto, Akhmadu Muradi, Ihza Fachriza, Myranda Zahrah Putri, Stacy Gabriella
Mutation And Variant Of Coronavirus Disease 2019 (Covid-19): Review Of Current Literatures, Adityo Susilo, Chyntia Olivia Maurine Jasirwan, Syahidatul Wafa, Suzy Maria, Wulyo Rajabto, Akhmadu Muradi, Ihza Fachriza, Myranda Zahrah Putri, Stacy Gabriella
Jurnal Penyakit Dalam Indonesia
Since March 2020, the Coronavirus Disease 2019 (COVID-19) pandemic has engulfed the world, including Indonesia, for nearly two years. SARS-CoV-2 has undergone several mutations during its evolution as a pathogen, resulting in various variants of global concern. Variants of this virus are suspected to impede the outbreak resolution and possibly causing the outbreak to spiral out of control. There is still considerable debate and research underway regarding the new SARS-CoV-2 variants. Rapid transmission mechanisms and widespread vaccination coverage have accelerated the virus’s mutation rate and resulted in numerous new variants. To date, this has resulted in the discovery of a …
Full Issue: The International Undergraduate Journal Of Health Sciences, Volume 1, Issue 1, June 2021
Full Issue: The International Undergraduate Journal Of Health Sciences, Volume 1, Issue 1, June 2021
International Undergraduate Journal of Health Sciences
The full June 2021 issue (Volume 1, Issue 1) of the International Undergraduate Journal of Health Sciences
The Molecular Biology And Treatment Of Malignant Melanoma With Brafv600 Mutations, Michael P. Mullane
The Molecular Biology And Treatment Of Malignant Melanoma With Brafv600 Mutations, Michael P. Mullane
Journal of Patient-Centered Research and Reviews
Since 2011, the treatment options for metastatic malignant melanoma have significantly changed. In that year, ipilimumab, an anti-CTLA4 monoclonal antibody, and vemurafenib, a potent inhibitor of mutated-BRAF (V600E and V600K), were approved by the U.S. Food and Drug Administration (FDA). In 2013, dabrafenib, another inhibitor of mutated-BRAF, and trametinib, a MEK inhibitor, were approved by the FDA. Most recently, combination therapy with dabrafenib and trametinib was approved. This article will describe a patient with metastatic malignant melanoma with BRAFV600E who has responded very well to vemurafenib monotherapy. We will then explore the molecular basis, pharmacologic development and clinical outcomes …